Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

Table 4 Correlations of the changes between markers for body composition and the markers for cardio-metabolic risks in patients with type 2 diabetes

	Delta EFV		Delta LAI		Delta VFA		Delta SFA
	r	p values	r	p values	r	p values	r	p values
Changes in body composition markers
Body weight (kg)	0.301	0.113	−0.616	0.003	0.686	0.001	0.250	0.159
Body mass index (kg/m²)	0.387	0.046	−0.531	0.012	0.719	<0.001	0.292	0.120
EFV	NA		0.154	0.264	−0.237	0.164	−0.075	0.379
LAI	0.154	0.264	NA		−0.391	0.049	−0.168	0.245
VFA (cm²)	−0.237	0.164	−0.391	0.049	NA		0.272	0.130
SFA (cm²)	−0.075	0.379	−0.168	0.245	0.023	0.463	NA
Body fat (%)	0.103	0.342	−0.468	0.025	0.296	0.117	−0.149	0.277
Total fat mass (kg)	0.166	0.255	−0.723	<0.001	0.284	0.127	0.082	0.374
Total non-fat mass (kg)	−0.063	0.402	0.224	0.186	−0.255	0.154	−0.082	0.374
Skeletal muscle index	0.187	0.229	−0.154	0.271	0.143	0.285	0.350	0.047
Changes in cardio-metabolic markers
HbA1c (%)	0.256	0.152	−0.150	0.277	0.073	0.387	0.282	0.128
HOMA-IR	−0.271	0.155	0.315	0.118	0.306	0.117	0.094	0.364
ALT (U/l)	−0.044	0.490	−0.170	0.251	0.249	0.159	−0.203	0.210
Log CRP (mg/l)	0.493	0.019	−0.453	0.029	−0.039	0.438	0.302	0.112
Log ACR (mg/g)	−0.069	0.393	0.042	0.434	0.333	0.048	−0.069	0.393
Adiponectin (μg/ml)	−0.228	0.189	0.154	0.264	−0.167	0.261	−0.571	0.008
Leptin (ng/ml)	0.146	0.295	0.115	0.330	0.378	0.044	−0.138	0.305
Log interleukin 6 (pg/ml)	−0.411	0.064	−0.318	0.115	0.296	0.142	0.007	0.490

ACR albumin-to-creatinine ratio, ALT alanine transaminase, CRP C-reactive protein, DBP diastolic blood pressure, EFV epicardial fat volume, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment as an index of insulin resistance, LAI liver attenuation index, SBP systolic blood pressure, SFA subcutaneous fat area, VFA visceral fat area

ISSN: 1475-2840